Bio-Manguinhos/Fiocruz COVID-19 (mRNA) Vaccine Booster

Starting soon · Phase 1

Conditions studied: Severe Acute Respiratory Syndrome (SARS-CoV-2 Virus)

In brief

This is a descriptive, open-label, multicenter, non-randomized, uncontrolled phase I clinical study to evaluate the safety, reactogenicity, and immunogenicity of the COVID-19 Vaccine (mRNA) - Bio-Manguinhos/Fiocruz at doses of 25 μg, 50 μg, and 100 μg in healthy adults aged 18 to 59 years. Each study cohort (25 μg, 50 μg, and 100 μg) will initially include a sentinel group of five participants, who will be included sequentially, one by one. This inclusion will allow for an initial integrated risk-benefit assessment, evaluating whether the data from the included participant maintain the risk within acceptable limits for progression.

Key facts

Study ID

NCT07640308

Run by

The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)

People needed

90

Starts

2026-07-01

Expected to finish

2028-01-01

Last updated by the study team

2026-06-10

Who can join

Age: 18 and older, up to 59. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women aged between 18 and 59 years.
• Negative result for SARS-CoV-2 in a rapid antigen test at screening (Visit 1) and at the inclusion visit (Visit 0).
• Body Mass Index >18.9 and <35.0 kg/m².
• Body weight ≥50.0 kg for men and ≥45.0 kg for women.
• Complete primary vaccination for COVID-19, and at least one more booster dose, with the last booster being an mRNA vaccine approved by Anvisa.
• At least one booster dose with an mRNA-based vaccine, with the last booster given at least 6 months prior to the enrollment date (proven by a vaccination certificate or registration in the SI-PNI system).
• Participants with the potential to become pregnant (PPE), as well as men with PPE partners, must agree to use effective contraceptive methods throughout the study participation period.
• Ability to understand the study, its objectives, risks, and procedures, and to provide free and informed consent.

You may not qualify if…

• Presence of any active infection at the time of vaccination or fever up to 7 days before the V0 visit. Participants in this condition may be rescheduled.
• Administration of another vaccine up to 28 days before or planning to receive another vaccine within 29 days following the V0 visit.
• Absolute or relative contraindications to the mRNA-based COVID-19 vaccine:
• Confirmed prior anaphylaxis to mRNA vaccines or any of their components, especially polyethylene glycol (PEG).
• History of anaphylaxis to other vaccines or injectable medications.
• History of myocarditis or pericarditis prior to vaccination.
• History of multisystem inflammatory syndrome (MIS-C or MIS-A).
• Previous diagnosis of immunodeficiency, autoimmune diseases, or cardiomyopathies.
• Medium or large surgery performed up to 3 months prior to inclusion.
• History of malignant neoplasm in the 12 months prior to screening (V-1).
• Uncontrolled coagulopathy or any hematological condition that contraindicates intramuscular injection.
• Presence of decompensated or uncontrolled chronic disease at the time of inclusion. At the investigator's discretion, participants with stable chronic disease may be included.
• Use of immunosuppressive medications in the 3 months prior to vaccination.
• History of antineoplastic chemotherapy treatment.
• Planning for the use of immunosuppressants or chemotherapeutic agents during the study period.
• Current use of corticosteroids at immunosuppressive doses. Immunosuppressive doses are considered to be ≥10 mg/day of prednisone (or equivalent) systemically for 14 days or more.
• Use of blood products in the 3 months prior to inclusion.
• Participation in another clinical study using an investigational product in the 12 months prior to inclusion.
• Pregnancy or lactation at the time of visit V0, or planning to become pregnant during the study period.
• Positive pregnancy test result at screening (visit V1) or on the day of vaccination (applicable to PEP).
• Presence of tattoos, scars, discoloration, or any skin alteration at the application site that, in the investigator's opinion, may interfere with the assessment of local reactogenicity.
• Any medical, psychological, or social condition that, in the investigator's opinion, may compromise the participant's safety, adherence to the protocol, or the integrity of the data.
• Clinically significant changes in screening laboratory tests (visit V1):
• Hemoglobin ≤ 10.9 g/dL;
• White blood cells < 2,500 cells/mm³;

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.